Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

Prism Pharmaceuticals Receives FDA Approval of Ready-to-Use NEXTERONE Premixed Injection

By Pharmaceutical Processing | November 18, 2010

Prism Pharmaceuticals, Inc. announced today that the FDA has
approved the supplemental new drug application for NEXTERONE (amiodarone HCl)
Premixed Injection, the first and only premixed intravenous (IV) bag
formulation of the antiarrhythmic agent amiodarone IV. NEXTERONE Premixed
Injection is indicated for initiation of treatment and prophylaxis of
frequently recurring ventricular fibrillation (VF) and hemodynamically unstable
ventricular tachycardia (VT) in patients refractory to other therapy.

NEXTERONE Premixed Injection is approved in two ready-to-use
dosage forms with strengths of 1.5 mg/mL (150 mg/100 mL) for rapid loading infusion
and 1.8 mg/mL (360 mg/200 mL) for subsequent infusion.

“Until now, amiodarone IV required admixture at time of
use. NEXTERONE Premixed Injection overcomes the need to admix amiodarone IV,
thereby eliminating the potential for medication admixture error,” said Dr. Warren D. Cooper, President and CEO of Prism. “The
ready-to-use packaging is designed for the storage of NEXTERONE Premixed
Injection at the point of use in automated dispensing cabinets and crash carts and
offers a two-year shelf life.” Manufacturer-prepared, premixed
ready-to-use products represent a preferred approach, when available, to
advance initiatives and professional standards for improving IV drug
safety.Organizations that promote, support, and monitor implementation of
practices intended to assure quality services in the hospital environment
include the Joint Commission, the United States Pharmacopeia (USP)
and the American Society of Health System Pharmacists (ASHP).

 

 

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE